Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515302 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL13300994 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL6496554 | 1.00 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL9277821 | 0.97 | OPRM1 (0.39) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| Iodide SCHEMBL28150638 | 0.97 | OPRM1 (0.36) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| Water SCHEMBL28150547 | 0.97 | OPRM1 (0.36) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL10856987 | 0.97 | OPRM1 (0.34) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL27466489 | 0.95 | CCR5 (0.36) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL10862803 | 0.94 | OPRM1 (0.33) | GRIN1GRIN2AGRIN2BPRCPSIGMAR1 | |
| SCHEMBL24176112 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117003199-A | Dehydrogenation method and hydrogen production system using same | 现代自动车株式会社 | 2023-11-07 | — | — | CN | claimed |
| US-20230348266-A1 | DEHYDROGENATION METHOD AND HYDROGEN PRODUCTION SYSTEM USING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2023-11-02 | — | — | US | claimed |
| WO-2021119464-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2021-06-17 | — | — | WO | claimed |
| CN-104245585-A | Process for preparing aluminosilicate zeolite SSZ-33 | CHEVRON USA INC | 2014-12-24 | — | — | CN | claimed |
| WO-2012044963-A2 | PERFLUOROCARBONS FOR USE IN TREATING PRURITUS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| EP-2419392-A2 | EMULSIONS OF PERFLUOROCARBONS | Oxygen Biotherapeutics, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010121082-A2 | EMULSIONS OF PERFLUOROCARBONS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| CN-117003199-A | Dehydrogenation method and hydrogen production system using same | 现代自动车株式会社 | 2023-11-07 | — | — | CN | disclosed |
| US-20230348266-A1 | DEHYDROGENATION METHOD AND HYDROGEN PRODUCTION SYSTEM USING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2023-11-02 | — | — | US | disclosed |
| WO-2021119464-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-2758034-A1 | COMPOSITIONS AND METHODS FOR MOLECULAR IMAGING OF OXYGEN METABOLISM | Rockland Technimed Ltd. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043236-A1 | COMPOSITIONS AND METHODS USEFUL FOR REALTIME IN SITU PHYSIOLOGICAL MOLECULAR IMAGING OF OXYGEN METABOLISM | ROCKLAND TECHNIMED, LTD. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013044186-A1 | COMPOSITIONS AND METHODS FOR MOLECULAR IMAGING OF OXYGEN METABOLISM | ROCKLAND TECHNIMED, LTD. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| EP-1361880-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| CN-1454084-A | Emulsion of perfluororganic compounds for medical purposes, method for producing said emulsion and methods for curing and preventing diseases with the aid of the emulsion | OTKRYTOE AKTSIONERNOE OBSCHEST (RU) | 2003-11-05 | — | — | CN | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| EP-0666736-A1 | STABILIZATION OF FLUOROCARBON EMULSIONS. | ALLIANCE PHARMA (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009625-A2 | STABILIZATION OF FLUOROCARBON EMULSIONS | ALLIANCE PHARMACEUTICAL CORP. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | GRIN1 618/4885GRIN2A 1452/4885GRIN2B 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.